Cancer Genetics (Cancer Genetics) Equity-to-Asset : 0.48 (As of Dec. 2020)

Cancer Genetics Equity-to-Asset Chart

Cancer Genetics Annual Data
	Trend	Dec11	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20
Equity-to-Asset		Get a 7-Day Free Trial					0.60	0.51	0.19	0.50	0.48

Cancer Genetics Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Equity-to-Asset	Get a 7-Day Free Trial															0.50	0.45	0.43	0.50	0.48

Competitive Comparison of Cancer Genetics's Equity-to-Asset

For the Biotechnology subindustry, Cancer Genetics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cancer Genetics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cancer Genetics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Cancer Genetics's Equity-to-Asset falls into.

Cancer Genetics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Cancer Genetics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Cancer Genetics's Equity to Asset Ratio for the quarter that ended in Dec. 2020 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cancer Genetics  (NAS:CGIX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Cancer Genetics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Cancer Genetics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Genetics (Cancer Genetics) Business Description